Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality

JAMA

Volumn 308, Issue 14, 2012, Pages 1469-1475

  Melander, Olle ^a,b,c   Maisel, Alan S ^d   Almgren, Peter ^a   Manjer, Jonas ^a,c   Belting, Mattias ^b,c   Hedblad, Bo ^a,c   Engström, Gunnar ^a   Kilger, Ute ^e   Nilsson, Peter ^a,c   Bergmann, Andreas ^e,f   Orho Melander, Marju ^a  

^a LUND UNIVERSITY   (Sweden)

^b Section of Oncology   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^e SPHINGOTEC GMBH   (Germany)

^f Hohen Neuendorf   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROTENSIN; PRONEUROTENSIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84867177612     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.12998     Document Type: Article

References (33)

1. Sjöström CD, Lissner L, Wedel H, Sjöström L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999;7(5):477-484.
2. Sjöström L, Gummesson A, Sjöström CD, et al; Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7):653-662.
3. Sjöström L, Narbro K, Sjöström CD, et al; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357(8):741-752.
4. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56-65.
5. Carraway R, Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem. 1973;248(19):6854-6861.
6. Kitabgi P, Carraway R, Leeman SE. Isolation of a tridecapeptide from bovine intestinal tissue and its partial characterization as neurotensin. J Biol Chem. 1976;251(22):7053-7058.
7. Minamino N, Kangawa K, Matsuo H. Neuromedin N: a novel neurotensin-like peptide identified in porcine spinal cord. Biochem Biophys Res Commun. 1984;122(2):542-549.
8. Kalafatakis K, Triantafyllou K. Contribution of neurotensin in the immune and neuroendocrine modulation of normal and abnormal enteric function. Regul Pept. 2011;170(1-3):7-17.
9. Vincent JP, Mazella J, Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol Sci. 1999;20(7):302-309.
10. Kitabgi P. Prohormone convertases differentially process pro-neurotensin/neuromedin N in tissues and cell lines. J Mol Med (Berl). 2006;84(8):628-634.
11. Cooke JH, Patterson M, Patel SR, et al. Peripheral and central administration of xenin and neurotensin suppress food intake in rodents. Obesity (Silver Spring). 2009;17(6):1135-1143.
12. Kim ER, Mizuno TM. Role of neurotensin receptor 1 in the regulation of food intake by neuromedins and neuromedin-related peptides. Neurosci Lett. 2010;468(1):64-67.
13. Wisén O, Björvell H, Cantor P, Johansson C, Theodorsson E. Plasma concentrations of regulatory peptides in obesity following modified sham feeding (MSF) and a liquid test meal. Regul Pept. 1992;39(1):43-54.
14. Christ-Crain M, Stoeckli R, Ernst A, et al. Effect of gastric bypass and gastric banding on proneurotensin levels in morbidly obese patients. J Clin Endocrinol Metab. 2006;91(9):3544-3547.
15. Holdstock C, Zethelius B, Sundbom M, Karlsson FA, Edén EngströmB. Postprandial changes in gut regulatory peptides in gastric bypass patients. Int J Obes (Lond). 2008;32(11):1640-1646.
16. Dupouy S, Mourra N, Doan VK, Gompel A, Alifano M, Forgez P. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie. 2011;93(9):1369-1378.
17. Evers BM. Neurotensin and growth of normal and neoplastic tissues. Peptides. 2006;27(10):2424-2433.
18. Dupouy S, Viardot-Foucault V, Alifano M, et al. The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS One. 2009;4(1):e4223.
19. SouazéF, Dupouy S, Viardot-Foucault V, et al. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res. 2006;66(12):6243-6249.
20. Kathiresan S, Voight BF, Purcell S, et al; Myocardial Infarction Genetics Consortium; Wellcome Trust Case Control Consortium. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet. 2009;41(3):334-341.
21. Musunuru K, Strong A, Frank-Kamenetsky M, et al. From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nature. 2010;466(7307):714-719.
22. Ernst A, Hellmich S, Bergmann A. Proneurotensin 1-117, a stable neurotensin precursor fragment identified in human circulation. Peptides. 2006;27(7):1787-1793.
23. Friry C, Feliciangeli S, Richard F, Kitabgi P, Rovere C. Production of recombinant large proneurotensin/ neuromedin N-derived peptides and characterization of their binding and biological activity. Biochem Biophys Res Commun. 2002;290(4):1161-1168.
24. Minisymposium: The MalmöDiet and Cancer Study: Design, biological bank and biomarker programme, 23 October 1991, Malmo, Sweden. J Intern Med. 1993;233(1):39-79.
25. Persson M, Berglund G, Nelson JJ, Hedblad B. Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmö, Sweden. Atherosclerosis. 2008;200(1):191-198.
26. Belting M, Almgren P, Manjer J, et al. Vasoactive peptides with angiogenesis-regulating activity predict cancer risk in males. Cancer Epidemiol Biomarkers Prev. 2012;21(3):513-522.
27. Enhörning S, Wang TJ, Nilsson PM, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation. 2010;121(19):2102-2108.
28. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009;302(1):49-57.
29. Rosvall M, Janzon L, Berglund G, Engström G, Hedblad B. Incident coronary events and case fatality in relation to common carotid intima-media thickness. J Intern Med. 2005;257(5):430-437.
30. Rosvall M, Janzon L, Berglund G, Engström G, Hedblad B. Incidence of stroke is related to carotid IMT even in the absence of plaque. Atherosclerosis. 2005;179(2):325-331.
31. Alexander MJ. Estrogen-regulated synthesis of neurotensin in neurosecretory cells of the hypothalamic arcuate nucleus in the female rat. Endocrinology. 1993;133(4):1809-1816.
32. Watters JJ, Dorsa DM. Transcriptional effects of estrogen on neuronal neurotensin gene expression involve cAMP/protein kinase A-dependent signaling mechanisms. J Neurosci. 1998;18(17):6672-6680.
33. Morris NJ, Ross SA, Lane WS, et al. Sortilin is the major 110-kDa protein in GLUT4 vesicles from adipocytes. J Biol Chem. 1998;273(6):3582-3587.